Fly News Breaks for March 25, 2019
Mar 25, 2019 | 10:49 EDT
Piper Jaffray analyst Christopher Raymond says that while details were limited with the data embargoed, he views this morning's announcement from Aimmune Therapeutics as "de-risking." It provides another set of Phase 3 safety and efficacy data for AR101, Raymond tells investors in a research note. He expects more clarity in June when the data are presented, but adds that management commentary indicates efficacy and safety are in line with the Phase 3 Palisade data. Raymond continues to like the set-up for the shares and remains a buyer of Aimmune with an Overweight rating and $60 price target.
News For AIMT From the Last 2 Days
Jun 17, 2019 | 06:25 EDT
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.